Malaria due to Plasmodium falciparum remains a significant infectious disease linked to poverty that is of public health concern despite progress made in recent years. According to the 2023 World Malaria Report, an estimated 249 million malaria cases and 608 deaths were recorded in 85 malaria-endemic countries and territories in 2022, an increase of 5 million cases compared to 2021 [1] . The WHO African Region, with an estimated 233 million cases in 2022, accounted for about 94% of cases globally. Pregnant women, especially primigravida mothers, have an increased susceptibility to malaria infection due to their reduced immunity arising from immunological, hormonal, and physiological changes [2] [3] , making them more prone to severe complications, including maternal anemia, low birth weight, and maternal mortality [4] [5] . In 2022, more than 13 million malaria cases were reported among pregnant women globally [6] .

Malaria is endemic across all ten regions of Cameroon and is the first major cause of morbidity and mortality among pregnant women. The country is ranked among the 15 highest-burden malaria countries worldwide, contributing over 3% of all global malaria cases and deaths [7] . The prevalence of MiP recorded in 2021 in Cameroon was 39.8% [8] . A pregnant woman suffering from malaria is estimated to be three times more at risk of dying of the disease compared to a non-pregnant woman suffering from the disease [9] . To mitigate these risks of MiP, the World Health Organization (WHO) recommends Intermittent Preventive Treatment with sulfadoxine-pyrimethamine (IPTp-SP) as a cost-effective and proven intervention to prevent malaria transmission. Pregnant women in malaria-endemic zones take IPTp-SP regardless of whether they are symptomatic of malaria. The IPTp-SP policy recommends that each pregnant woman receive at least three doses of sulfadoxine-pyrimethamine (SP) during pregnancy, starting at 13 weeks of gestation, with doses at least one-month intervals till delivery [10] [11] .

In Cameroon, the Ministry of Public Health adopted this protocol in 2004, integrating IPTp-SP with additional preventive measures such as free distribution of long-lasting insecticidal nets (LLINs) and folic acid supplementation as part of antenatal care (ANC) services. [12] . However, coverage has remained below national targets, with recent surveys reporting suboptimal IPTp-SP uptake across several regions. Existing literature in the country revealed that over 54% of pregnant women received at least two doses of intermittent preventative treatment of malaria in pregnancy (IPTp2) in 2018. The proportion of pregnant women who received at least three doses (IPTp3) increased from 26% in 2014 to 32% in 2018 [7] . Recent studies recorded an optimal uptake of 54.9% in 2022 and 65.0% in 2024 within the country’s North West [13] and West [14] regions. These observations fall short of the country’s target coverage rate of 80% by 2023.

Identifying factors and barriers that limit IPTp-SP uptake in high-burden areas is crucial for strengthening MiP interventions. This study, therefore, aimed to assess the uptake of IPTp-SP during pregnancy and associated factors in Bonassama District Hospital, Littoral Region of Cameroon, a region characterized by high malaria transmission. The findings will provide valuable insights to guide strategies for improving malaria prevention during pregnancy.

Intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) remains a key intervention recommended by the World Health Organization (WHO) to reduce morbidity and mortality associated with malaria during pregnancy. To evaluate the impact of this control measure, there is a need to periodically report the uptake of IPTp-SP in malaria-endemic areas. This study sought to assess the uptake of intermittent preventive treatment with Sulphadoxine pyrimethamine during pregnancy (IPTp-SP) and associated factors in Bonassama District Hospital. This study’s most represented age group was 25 - 34 years. Studies in Cameroon [14] and Kenya [19] reported similar results, with women aged 24 - 34 being the most represented.

Our results showed that 98.5% of the pregnant women had taken at least one dose of IPTp-SP. Similar results were observed in studies conducted in various parts of Cameroon: Bamenda (98.35%) by Diengou et al. [20] , Southwest (92.9%) by Anchang-Kimbi et al. [21] , Littoral (94.9%) by Moukoko et al. [22] . The World Health Organisation (WHO) recommends optimal uptake of three or more doses of IPTp-SP during pregnancy and coverage of at least 80% [11] [20] . However, our study recorded an optimal uptake of IPTp-SP of 69.5%, similar to the optimal uptake of IPTp-SP of 64.99% in a recent study conducted in the western part of the country by Kamga et al. [14] . Contrary to our results, lower optimal uptake was obtained in other parts of Cameroon: South West (47.0%) [21] and North West (54.9%) [13] regions. Moreover, 36.8% was obtained among women in Northern Nigeria in 2012, and 55.1% of women in private health facilities in Ghana in 2019 [23] [24] . Despite this variation, it’s interesting to note that, though optimal uptake is lower than the WHO recommended target, endemic countries progressively adhere to it from 2012 to 2024. The differences in optimal uptakes might be due to challenges in implementation, level of compliance, and intensity of malaria transmission. The combination of sulfadoxine-pyrimethamine is recommended for malaria prophylaxis because it blocks the parasite’s utilization of folinic acid, killing the parasite [25] .

Our study also revealed a significant association between the uptake of IPTp-SP and asymptomatic malaria infection. Women who had taken the optimal doses recommended for IPTp-SP (≥3) had fewer P. falciparum infections than their counterparts who had taken less than three doses. Interestingly, other studies in the Southwest of Cameroon in 2020 and 2022 and Littoral, Cameroon in 2023 reported similar results [21] [22] [26] . This confirms that optimal doses of IPTp-SP protect against malaria [11] [27] . Although our study did not reveal any significance between good knowledge of transmission and prevention, most of those with good knowledge received optimal doses of SP. These women might have been counseled against the dangers of malaria infection during pregnancy in health talks given during ANC. A study carried out in six districts of Tanzania reported similar results [28] . Moreover, studies conducted in Benin confirmed that women with comprehensive knowledge of malaria were almost 5 times more likely to receive optimal doses of IPTp-SP [29] .

Our results revealed some determinants of uptake of IPTp-SP, including level of education, religion, parity, gestational age at first ANC, number of ANC, malaria infection, and knowledge of the number of SP doses. Educational level was a great determinant of uptake of optimal doses of IPTp-SP [24] [28] [30] - [32] . Educated women are more likely to understand the devastating consequences of malaria in pregnancy, as revealed by our study, where women with a secondary level of education were 3 times more likely to receive the optimal dose of IPTp-SP compared to those with no level of education. This aligns with studies conducted in Nigeria by Kalu et al. [33] , who reported that apart from the household index and media exposure, a spouse’s education level positively influenced the uptake of optimal doses of IPTp-SP. This is contrary to a study conducted in Benin [29] and Cameroon [34] , where the level of education was not significantly associated with the uptake of IPTp-SP. This can be explained by the fact that there have been advances in knowledge due to increased awareness in recent years. It was also observed that primigravida women experiencing pregnancy for the first time with excitement were 3 times more likely to receive IPTp-SP compared to multigravida women who were acquainted with the situation. Nulliparous women were 4 times more likely to receive optimal IPTp-SP. This is possible because since it is their first experience, they fear losing their first child to malaria compared to those who have had multiple births. The period when women started ANC was significantly correlated to IPTp-SP uptake. Women who started ANC attendance in the first trimester of pregnancy were 29 times more likely to receive IPTp-SP than those who started during the second and third trimesters. This is comparable to studies conducted in Burundi, Western Kenya, and Ghana [19] [23] [28] [31] . The number of ANC visits was also positively correlated with the uptake of IPTp-SP in our study. Those with ≥4 ANC visits were about 8 times more likely to receive the optimal IPTp-SP dose. This corroborates with other studies that identified ANC visits as a determinant of uptake of IPTp-SP [19] - [22] [27] [30] . This is possible because, during such visits, women are constantly reminded of the consequences of malaria in pregnancy, both to the mother and the child, which is reflected in the optimal uptake of IPTp-SP.

Although our results did not show any significant association between utilization of LLINs and optimal uptake of IPTp-SP, women who always used LLINs (71.6%) tended to have received optimal SP doses compared to those who do not always use LLINs (66.4%). However, this differs from studies that reported LLIN utilization as a significant determinant of SP uptake [24] . When uptake was associated with malaria infection, our results revealed that women who received the optimal IPTp-SP doses were almost 3 times less likely to have malaria parasite infection than those who did not. This is similar to studies in Southwest Cameroon, where malaria prevalence was reduced in women with optimal uptake of IPTp-SP [21] . This shows that optimal uptake of IPTp-SP can prevent malaria, as confirmed by the fact that 76.1% of the participants with optimal uptake in our study were negative for malaria. Furthermore, other studies reported that there was more likelihood of malaria in Southeastern Nigerian women who failed to take optimal doses of IPTp-SP [35] . An understanding of the reasons why a drug is taken will always encourage the uptake of the drug. This study found that those with a good understanding of optimal IPTp-SP dose were 3 times more likely to receive optimal IPTp-SP dose. This was also reported by Badirou and colleagues [29] , who reported that women with adequate knowledge of IPTp-SP doses were 3.3 times more likely to receive optimal IPTp-SP doses. Other studies also supported that maternal knowledge of optimal doses was significantly associated with the uptake of IPTp-SP [19] .

In this study, the optimal uptake of ITPp-SP, as recommended by WHO, was 69.5%, though below the 80% coverage expected by 2030 in the country. Optimal uptake of IPTp-SP was found to be significantly associated with ANC attendance and malaria infection. Determinants of uptake of IPTp-SP included level of education, religion, parity, gestational age at first ANC, number of ANC, malaria infection, and knowledge of the number of SP doses. Healthcare providers should emphasize early ANC engagement through education and health talks, encouraging women to begin ANC within the first trimester to access timely IPTp-SP. Additionally, training healthcare staff in effective counseling techniques will help bridge literacy and knowledge gaps, enabling them to clearly and consistently convey the importance of IPTp-SP uptake.

This study employed a cross-sectional study design whose weakness is the impossibility of inferring causation. Only women in the third trimester of pregnancy (>30 weeks of gestation) were included in the study who could possibly attend another ANC or take another IPTp-SP dose. A study that included women attending postnatal care could give a better picture of the uptake of IPTp-SP doses. Moreover, some answers to questions, such as sleeping under LLINs, were self-reported by the participants and not observed by the researchers. However, self-reporting was minimized by verification of some responses using ANC clinic attendance booklets. In addition, with all survey data, the findings are limited by recall and social desirability biases. Finally, this study cannot be generalized to the whole population in Cameroon as the sample was selected from only one health facility. Expanding the study to multiple healthcare centers across different regions would also enhance generalizability, capturing a broader range of socio-demographic and health-seeking behaviors, which could offer more representative findings and better inform public health strategies.

MUA, IUA, and TOA conceived and designed the experiments. CKN, CMN, and SF conducted the study. MUA, TOA, KBW, and IUA performed the analysis. MUA, IUA, JN, and MA drafted the manuscript. All authors contributed to the revision of the manuscript before submission.

We appreciate the participants who made this study realistic. We thank the Director of the Bonassama District Hospital for the permission granted to conduct the study in the health facility.